Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a probiotic help pregnant women and their babies grow stronger?

NCT ID NCT05501470

Disease control Sponsor: Institut Pasteur de Dakar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a probiotic called Vivomixx can improve gut health in pregnant women in Senegal. Poor gut health, known as environmental enteric dysfunction, is linked to stunted growth in children. The trial involved 76 women who took either the probiotic or a placebo for 56 days, and researchers measured changes in gut inflammation and damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic Vivomixx
What this could lead to
If it works, this could point toward a simple probiotic treatment to improve gut health in pregnant women and potentially reduce childhood stunting.
What could go wrong
This is a small, early-phase proof-of-concept trial with only 76 participants. Results may not apply broadly, and the probiotic may not significantly improve gut health or stunting outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

76 people

The number who actually took part.

Started

Jun 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women over the age of 18, living in Guediawaye district, Senegal Exclusion Criteria: * • have had diarrhea, defined as the passage of three or more loose stools per 24 hours, in the preceding 14 days * have taken antibiotics or probiotics in the preceding 14 days * have taken non-steroidal anti-inflammatory drugs in the preceding 14 days * have any illness which in the opinion of the investigator will complicate assessment of safety or efficacy * have any gastrointestinal contraindication to ingestion of a capsule (known or suspected gastrointestinal obstruction, stricture, fistula, gastroparesis, or any swallowing disorder.) * have a plan to leave the study area within the follow-up period but may be enrolled if/when these disqualifiers have expired.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Environmental enteric dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Environmental enteric dysfunction

Contacts and locations

Locations

  • Centre de santé de Wakhinane

    Guédiawaye, Dakar, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.